Tamila Kindwall-Keller, DO
Hematology & Oncology · Cleveland, OHNPI 1871587246
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,759 of the $53,583 with a category attached, or 68.6%. National Marrow Donor Program accounts for 99.2% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $24,599, more than ten times the $2,400 reported in 2022.
Across 39 payments — averaging $1373.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- National Marrow Donor Program$53K
- Astellas Pharma US Inc$190
- Takeda Pharmaceuticals U.S.A., Inc.$103
- Incyte Corporation$71
- Bristol Myers Squibb$35
- Novartis$30
Across 8 payments — averaging $6647.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$42K
- E.r. Squibb & Sons, L.L.C.$10K
- National Marrow Donor Program$742
What the payments were for
- Consulting fees$16,39531%
- Speaking & faculty fees$36,75969%
- Food & beverage$2390%
- Education$1900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| National Marrow Donor Program | 32 | $53,154 |
| Astellas Pharma US Inc | 2 | $190 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $103 |
| Incyte Corporation | 1 | $71 |
| Bristol Myers Squibb | 2 | $35 |
| Novartis | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NINLARO$103
How this compares
$53,583 in reported general payments places this provider in the 85th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 36 | $652,625 |
| Lenalidomide | 38 | $507,625 |
| JakafiRuxolitinib Phosphate | 12 | $183,590 |
| TagrissoOsimertinib Mesylate | 11 | $174,649 |
| ValacyclovirValacyclovir Hcl | 166 | $6,981 |
| EliquisApixaban | 12 | $6,792 |
| Acyclovir | 32 | $2,012 |
| Omeprazole | 45 | $442 |
| Ondansetron OdtOndansetron | 22 | $408 |
| Dexamethasone | 31 | $178 |
| Hydroxyurea | 15 | $150 |
| Anastrozole | 11 | $117 |
| Amoxicillin | 12 | $70 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 26 | $52 |
| Promethazine Hcl | 13 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $35 | $652,62536 claims |
| Incyte CorporationJakafi | $71 | $183,59012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cleveland
- Hillard LazarusCleveland$2M
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Bachar DerghamCleveland$387K
- Brian HillCleveland$316K
- Dale ShepardCleveland$314K
- Sakti ChakrabartiCleveland$301K
- Keith McCraeCleveland$215K
- Megan KruseCleveland$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.